1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Flerie AB

Flerie AB

1.28
EUR
0.00
(0.00%)
155.19MMarket Cap
Jan 20Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
24.77
0.21
0.06
0.02
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-8.16
-16.39
-13.33
-14.3
-15.87
-14.62
-7.96
-18.65
-16.48
-9.92
-2.83
-9.4
- -
Free Cash Flow per Basic Share
-4.51
-20.27
-10.31
-13.24
-15.18
-14.17
-9.92
-22.46
-21.26
-1.31
-0.21
-0.35
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12.44
0.23
35.79
21.48
11.54
14.76
6.84
71.3
54.86
585.72
47.05
38.15
39.14
Tangible Book Value per Share
12.44
0.23
35.15
21.03
11.29
14.7
6.84
71.3
54.86
585.72
47.05
38.15
39.14
Basic Weighted Avg Shares
2
2
3
5
5
6
7
6
6
56
81
81
90
Sales/Revenue/Turnover
45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-26.98
-7,838.83
-22,471.02
-64,801.77
-64,060.94
-99,672.73
-163,854.29
- -
- -
- -
-105,600
- -
- -
Depreciation Expense
- -
- -
- -
1
1
1
1
1
1
1
1
1
- -
Net Income, GAAP
-15
-30
-41
-73
-82
-88
-57
-103
-100
-560
-228
-757
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-32.93
-7,947.07
-23,451.7
-64,312.39
-64,178.12
-99,742.05
-164,051.43
- -
- -
- -
-228,000
- -
- -
Working Capital
30
- -
181
108
64
106
47
432
333
436
1,006
713
550
LT Debt
- -
- -
2
1
- -
- -
2
- -
3
1
- -
2
1
Total Equity
30
1
182
109
64
107
49
434
334
3,566
4,198
3,377
3,394
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-193.09
-45.27
-49.95
-94.61
-102.66
-73.69
-42.64
-26.13
-28.7
-5.87
-19.98
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
89
95
87
Market Capitalization
2,895
3,025
1,719

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
727
783
558
Cash, Cash Equivalents & STI
540
585
306
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
14
8
8
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3,460.86%
344.55%
-19.56%
Free Cash Flow
12.94%
4.61%
65.29%
Net Income, GAAP
80.68%
141.46%
231.97%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
1
- -
2025
- -
9
- -
1
- -
2026
- -
1
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-283.69
1.39
-1.31
-0.72
-2.83
2025
-2.81
2.22
- -
-6.11
-9.4
2026
-0.68
-1.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ted Ingemar Jakob Fjällman
Full Time Employees
10
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Skeppsbron 16 Stockholm AB Sweden 111 30
IPO Date
Sep 11, 2016
Website
flerie.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Flerie AB (publ) is a dynamic life science investment firm, having listed publicly on Nasdaq Stockholm in mid-2024. It focuses on early-stage and growth opportunities within the biotechnology and pharmaceutical industries. The firm strategically invests in companies dedicated to advancing novel drug therapies and associated technological platforms that address significant medical needs globally. Flerie is committed to an active ownership model, providing resources and support across its diversified portfolio, primarily composed of around 30 innovative enterprises. Its investment reach spans Europe, the United States, and Israel. Established in 2011, the company maintains its primary operations in Stockholm, Sweden, complemented by an office in London, United Kingdom. A substantial capital raise completed in 2024 has further strengthened its capacity for strategic portfolio expansion and development.